253 related articles for article (PubMed ID: 25848016)
21. Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome.
Berg EL; Petkova SP; Born HA; Adhikari A; Anderson AE; Silverman JL
Mol Autism; 2021 Sep; 12(1):59. PubMed ID: 34526125
[TBL] [Abstract][Full Text] [Related]
22. Lovastatin suppresses hyperexcitability and seizure in Angelman syndrome model.
Chung L; Bey AL; Towers AJ; Cao X; Kim IH; Jiang YH
Neurobiol Dis; 2018 Feb; 110():12-19. PubMed ID: 29097328
[TBL] [Abstract][Full Text] [Related]
23. Understanding the pathogenesis of Angelman syndrome through animal models.
Jana NR
Neural Plast; 2012; 2012():710943. PubMed ID: 22830052
[TBL] [Abstract][Full Text] [Related]
24. Towards a therapy for Angelman syndrome by targeting a long non-coding RNA.
Meng L; Ward AJ; Chun S; Bennett CF; Beaudet AL; Rigo F
Nature; 2015 Feb; 518(7539):409-12. PubMed ID: 25470045
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of a TrkB agonist on spatial and motor learning in the
Schultz MN; Crawley JN
Learn Mem; 2020 Sep; 27(9):346-354. PubMed ID: 32817301
[TBL] [Abstract][Full Text] [Related]
26. From electrophysiology to chromatin: a bottom-up approach to Angelman syndrome.
Dan B; Servais L; Boyd SG; Wagstaff J; Cheron G
Ann N Y Acad Sci; 2004 Dec; 1030():599-611. PubMed ID: 15659843
[TBL] [Abstract][Full Text] [Related]
27. GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility.
Judson MC; Wallace ML; Sidorov MS; Burette AC; Gu B; van Woerden GM; King IF; Han JE; Zylka MJ; Elgersma Y; Weinberg RJ; Philpot BD
Neuron; 2016 Apr; 90(1):56-69. PubMed ID: 27021170
[TBL] [Abstract][Full Text] [Related]
28. Sleep disturbances in Ube3a maternal-deficient mice modeling Angelman syndrome.
Colas D; Wagstaff J; Fort P; Salvert D; Sarda N
Neurobiol Dis; 2005 Nov; 20(2):471-8. PubMed ID: 15921919
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic evidence for abnormal thalamocortical functioning in GABA receptor beta3 subunit-deficient mice, a model of Angelman syndrome.
Handforth A; Delorey TM; Homanics GE; Olsen RW
Epilepsia; 2005 Dec; 46(12):1860-70. PubMed ID: 16393151
[TBL] [Abstract][Full Text] [Related]
30. Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.
Judson MC; Burette AC; Thaxton CL; Pribisko AL; Shen MD; Rumple AM; Del Cid WA; Paniagua B; Styner M; Weinberg RJ; Philpot BD
J Neurosci; 2017 Aug; 37(31):7347-7361. PubMed ID: 28663201
[TBL] [Abstract][Full Text] [Related]
31. Ube3a reinstatement mitigates epileptogenesis in Angelman syndrome model mice.
Gu B; Carstens KE; Judson MC; Dalton KA; Rougié M; Clark EP; Dudek SM; Philpot BD
J Clin Invest; 2019 Jan; 129(1):163-168. PubMed ID: 30352049
[TBL] [Abstract][Full Text] [Related]
32. Assessing the requirements of prenatal UBE3A expression for rescue of behavioral phenotypes in a mouse model for Angelman syndrome.
Sonzogni M; Zhai P; Mientjes EJ; van Woerden GM; Elgersma Y
Mol Autism; 2020 Sep; 11(1):70. PubMed ID: 32948244
[TBL] [Abstract][Full Text] [Related]
33. Flurothyl-induced seizure paradigm revealed higher seizure susceptibility in middle-aged Angelman syndrome mouse model.
Egawa K; Nakakubo S; Kimura S; Goto T; Manabe A; Shiraishi H
Brain Dev; 2021 Apr; 43(4):515-520. PubMed ID: 33408038
[TBL] [Abstract][Full Text] [Related]
34. Altered serotonin, dopamine and norepinepherine levels in 15q duplication and Angelman syndrome mouse models.
Farook MF; DeCuypere M; Hyland K; Takumi T; LeDoux MS; Reiter LT
PLoS One; 2012; 7(8):e43030. PubMed ID: 22916201
[TBL] [Abstract][Full Text] [Related]
35. Delayed loss of UBE3A reduces the expression of Angelman syndrome-associated phenotypes.
Sonzogni M; Hakonen J; Bernabé Kleijn M; Silva-Santos S; Judson MC; Philpot BD; van Woerden GM; Elgersma Y
Mol Autism; 2019; 10():23. PubMed ID: 31143434
[TBL] [Abstract][Full Text] [Related]
36. Administration of CoQ10 analogue ameliorates dysfunction of the mitochondrial respiratory chain in a mouse model of Angelman syndrome.
Llewellyn KJ; Nalbandian A; Gomez A; Wei D; Walker N; Kimonis VE
Neurobiol Dis; 2015 Apr; 76():77-86. PubMed ID: 25684537
[TBL] [Abstract][Full Text] [Related]
37. Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells.
Grier MD; Carson RP; Lagrange AH
PLoS One; 2015; 10(4):e0124649. PubMed ID: 25894543
[TBL] [Abstract][Full Text] [Related]
38. Implications of slow waves and shifting epileptiform discharges in Angelman syndrome.
Yum MS; Lee EH; Kim JH; Ko TS; Yoo HW
Brain Dev; 2013 Mar; 35(3):245-51. PubMed ID: 22704603
[TBL] [Abstract][Full Text] [Related]
39. Behavioral Evaluation of Angelman Syndrome Mice at Older Ages.
Dutta R; Crawley JN
Neuroscience; 2020 Oct; 445():163-171. PubMed ID: 31730795
[TBL] [Abstract][Full Text] [Related]
40. Normal social seeking behavior, hypoactivity and reduced exploratory range in a mouse model of Angelman syndrome.
Allensworth M; Saha A; Reiter LT; Heck DH
BMC Genet; 2011 Jan; 12():7. PubMed ID: 21235769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
